 Beneficial effects calcium antagonist isradipine apolipoproteins hypertensive patients objective study effects calcium antagonist isradipine plasma lipids lipoproteins apolipoproteins patients essential hypertension four-week placebo wash-out period patients men women double-blind crossover study sustained-release isradipine isradipine SR standard isradipine formulation Nineteen patients mg/day patients mg/day Lipids end placebo period weeks treatment isradipine treatment groups lipid lipoproteins A-I levels ratio apolipoprotein A-I concentration irrespective gender data levels plasma A-I strong predictor coronary heart disease isradipine formulation mechanisms effect remain